Related Experiment Video
Updated: Dec 3, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
The Association Between Switching from Synthroid® and Clinical Outcomes: US Evidence from a Retrospective Database
James V Hennessey1, Ramon Espaillat2, Yinghui Duan2
1Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA.
Switching levothyroxine formulations increases the risk of out-of-range thyroid-stimulating hormone (TSH) levels and adverse clinical outcomes. Continuous Synthroid® use is associated with better TSH control and fewer negative health events.
Area of Science:
- Endocrinology
- Pharmacology
- Public Health
Background:
- Clinical guidelines advocate consistent levothyroxine therapy for hypothyroidism.
- Switching between synthetic levothyroxine formulations is discouraged.
Purpose of the Study:
- To compare clinical outcomes between continuous Synthroid® users and patients switching to alternative levothyroxine formulations.
- To assess the likelihood of adverse clinical outcomes associated with levothyroxine formulation switching.
Main Methods:
- Retrospective cohort analysis of electronic health records (May 2000-March 2016).
- Propensity score matching created cohorts of continuous Synthroid® users and switchers.
- Outcomes included out-of-range TSH levels and a composite endpoint of adverse clinical conditions.
Main Results:
- Switchers were more likely to have out-of-range TSH levels (OR 1.15; 95% CI 1.08-1.23).
- Switchers had a higher likelihood of the composite clinical endpoint (OR 1.23; 95% CI 1.12-1.37).
- Specific adverse outcomes like chronic kidney disease, depression, fatigue, and hypertension were more prevalent in switchers.
Conclusions:
- Findings support guidelines recommending against switching levothyroxine formulations.
- Continuous Synthroid® use is linked to better TSH control and reduced adverse clinical outcomes.
- Avoiding formulation switches is crucial for managing hypothyroidism effectively.
Related Concept Videos
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Therapeutic Drug Monitoring: Affecting Factors
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials
There are four phases in a clinical trial. A phase one...

